JP2024539157A5 - - Google Patents
Info
- Publication number
- JP2024539157A5 JP2024539157A5 JP2024523663A JP2024523663A JP2024539157A5 JP 2024539157 A5 JP2024539157 A5 JP 2024539157A5 JP 2024523663 A JP2024523663 A JP 2024523663A JP 2024523663 A JP2024523663 A JP 2024523663A JP 2024539157 A5 JP2024539157 A5 JP 2024539157A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270629P | 2021-10-22 | 2021-10-22 | |
| US63/270,629 | 2021-10-22 | ||
| PCT/US2022/078530 WO2023070097A2 (en) | 2021-10-22 | 2022-10-21 | Factor xi a2 domain-binding antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024539157A JP2024539157A (ja) | 2024-10-28 |
| JP2024539157A5 true JP2024539157A5 (https=) | 2025-10-22 |
| JPWO2023070097A5 JPWO2023070097A5 (https=) | 2025-10-22 |
Family
ID=84360943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523663A Pending JP2024539157A (ja) | 2021-10-22 | 2022-10-21 | 第ｘｉ因子ａ２ドメイン結合抗体及びそれらの使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12304969B2 (https=) |
| EP (1) | EP4419142A2 (https=) |
| JP (1) | JP2024539157A (https=) |
| KR (1) | KR20240099304A (https=) |
| CN (1) | CN118414168A (https=) |
| AU (1) | AU2022368930A1 (https=) |
| CA (1) | CA3235457A1 (https=) |
| CL (1) | CL2024001237A1 (https=) |
| CO (1) | CO2024006258A2 (https=) |
| IL (1) | IL312308A (https=) |
| MX (1) | MX2024004849A (https=) |
| WO (1) | WO2023070097A2 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US8388959B2 (en) | 2008-12-18 | 2013-03-05 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| TWI736575B (zh) * | 2016-01-22 | 2021-08-21 | 美商默沙東藥廠 | 抗凝固因子ｘｉ抗體 |
| CA3125303A1 (en) | 2019-01-21 | 2020-07-30 | Aronora Inc. | Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof |
-
2022
- 2022-10-21 WO PCT/US2022/078530 patent/WO2023070097A2/en not_active Ceased
- 2022-10-21 KR KR1020247016447A patent/KR20240099304A/ko active Pending
- 2022-10-21 MX MX2024004849A patent/MX2024004849A/es unknown
- 2022-10-21 US US18/048,644 patent/US12304969B2/en active Active
- 2022-10-21 EP EP22809619.4A patent/EP4419142A2/en active Pending
- 2022-10-21 CA CA3235457A patent/CA3235457A1/en active Pending
- 2022-10-21 IL IL312308A patent/IL312308A/en unknown
- 2022-10-21 CN CN202280084047.3A patent/CN118414168A/zh active Pending
- 2022-10-21 JP JP2024523663A patent/JP2024539157A/ja active Pending
- 2022-10-21 AU AU2022368930A patent/AU2022368930A1/en active Pending
-
2024
- 2024-04-19 CL CL2024001237A patent/CL2024001237A1/es unknown
- 2024-05-16 CO CONC2024/0006258A patent/CO2024006258A2/es unknown